Analysts at StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO – Get Free Report) in a research report issued on Monday. The brokerage set a “hold” rating on the stock.
Several other brokerages have also recently issued reports on EKSO. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Ekso Bionics in a research report on Tuesday, July 30th. Lake Street Capital began coverage on Ekso Bionics in a research report on Monday, June 24th. They issued a “buy” rating and a $2.50 target price on the stock.
Get Our Latest Stock Analysis on EKSO
Ekso Bionics Price Performance
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last announced its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The firm had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. During the same period in the previous year, the business posted ($0.31) earnings per share. On average, sell-side analysts forecast that Ekso Bionics will post -0.42 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC lifted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) by 322.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by institutional investors.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Recommended Stories
- Five stocks we like better than Ekso Bionics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What is the Dow Jones Industrial Average (DJIA)?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What is the Euro STOXX 50 Index?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.